The current guidelines for percutaneous coronary intervention do not address the prolonged postprocedural use of unfractionated heparin (UFH) to prevent acute occlusion. However, recently published small studies have yielded mixed results, leaving the question unanswered. Hence, we performed a meta-analysis of the existing evidence to assess the safety and efficacy of prolonged infusion of UFH after percutaneous coronary intervention. A systematic review of literature revealed seven studies involving 2412 patients. End points analyzed were ischemic complications (acute closure, myocardial infarction, and repeat revascularization) and major vascular complications (hematoma, arteriovenous fistula, pseudoaneurysm, and retroperitoneal bleed). Because the studies were homogenous for outcomes, combined relative risks across all the studies and the 95% confidence intervals were computed using the Mantel-Haenszel fixed-effect model. A two-sided alpha error ,0.05 was considered to be statistically significant. There were no significant differences in patient demographics between both groups. Compared with placebo, the risk of major vascular complication was significantly higher in patients getting postprocedural UFH for prolonged hours (relative risk, 2.24; confidence interval, 1.68-3.48; P = 0.001). However, the risk of ischemic complications was similar in both groups (relative risk, 0.95; confidence interval, 0.46-1.96; P = 0.89). The meta-analysis suggests that routine infusion of UFH after uncomplicated percutaneous coronary intervention may result in increased vascular complications without any reduction in incidence of ischemic complications.
INTRODUCTION
Percutaneous coronary intervention (PCI) has now been successfully performed for management of stable angina and acute coronary syndromes for many years.
Despite the experience gained during these years and recent advances in technology, postprocedural complications are not uncommon. The bulk of post-PCI cardiac complications is the result of ischemia caused by acute vessel occlusion. 1 Activation of the platelet system and the coagulation cascade resulting from plaque disruption or erosion results in formation of thrombus causing transient occlusion of coronary vessels. 2 The resultant adverse cardiovascular outcomes considerably augment the morbidity and expense of treatment. Owing to its ability to deactivate thrombin and factor Xa, use of unfractionated heparin (UFH) during the procedure has shown significant reduction in the incidence of acute ischemic complications. 3 Heparin use during urgent and elective PCI is well established, but a minimum required dose has not been defined when using contemporary interventional techniques. 4 The recent American College of Cardiology/American Heart Association/Society for Cardiac Angiography and Interventions guideline update recommends use of UFH during PCI, but it does not address prolonged postprocedural use of the same. 5 However, certain centers and operators continue to use UFH for 12 to 24 hours after PCI. 6 Studies in the past have shown that routine use of UFH after PCI is associated with increased bleeding complications, but it does not prevent ischemic events. On the contrary, there are data to suggest that prolonged postprocedural use of UFH is not related with greater risk of vascular complications, leaving the question unanswered. Meta-analysis of randomized trials may provide more reliable estimates of treatment effect than individual trials because they have more statistical power. 7, 8 Hence, we performed a systematic review and meta-analysis of the existing evidence to assess the safety and efficacy of prolonged infusion of UFH after PCI.
METHODS
A standardized protocol was used to identify the data for our analysis
Literature sources and search terms
Two independent reviewers (PS and RA) conducted comprehensive searches of the MEDLINE and Cochrane Central Register of Controlled Trials databases using web-based search engines (OVID, PubMed) for studies through June 2008. Search terms included unfractionated heparin, percutaneous coronary intervention, percuatenous transluminal coronary angioplasty, bleeding, myocardial infarction, vascular complications, ischemia as well as combinations. No language restriction was enforced. In addition, studies were identified through searches of the reference list of initially identified articles, abstracts, meeting proceedings, and pertinent available reviews. We also searched ongoing trials in clinicaltrials.gov, www.act.org.au, and www.controlled-trials.gov.
Trial selection
Preliminarily relevant citations were screened at the title or abstract level. Full reports were retrieved for those found potentially relevant. Decisions for retrieval were based on the independent appraisal of both reviewers (PS and RA) with divergences resolved by consensus. We included only prospective, randomized, controlled trials with postprocedure UFH infusion for 12 to 24 hours after PCI. Patients must also have received prior aspirin and UFH during the procedure. We assessed quality according to previously published criteria addressing effective randomization and objectivity of outcome assessment. 9, 10 We excluded the following studies from our analysis: 1) nonrandomized studies; 2) studies with postprocedural use of lowmolecular-weight heparin; 3) trials comparing different durations of postprocedural UFH infusion; and 4) trials not assessing the same clinical end points.
End points and definitions
Two clinical end points were extracted from each trial ( Table 1 ). End point definitions were those used in the individual trials. The primary efficacy outcome was the incidence of in-hospital ischemic complications, being a composite of death, myocardial infarction (MI), and revascularization. Death was defined as mortality from any cause. MI was defined as new, significant Q waves in two or more contiguous electrocardiographic leads or serum creatine kinase or creatine kinase-MB elevation to three or more times the upper limit of normal value. Urgent revascularization was defined as need for repeat revascularization of the previously treated vessel, either percutaneously or through coronary artery bypass grafting, resulting from evidence of ischemia. The primary safety end point was incidence of bleeding complications. Definitions of bleeding used by the various trials were heterogeneous, as described in Table 2 . For the purpose of this meta-analysis, we used a uniform definition of bleeding complication, defined as any bleeding requiring blood transfusion; major hematoma formation; or decrease in hemoglobin concentration of greater than 3 g/dL after the procedure.
Quality assessment
The two reviewers independently assessed the treatment allocation at baseline, concealment of treatment allocation, blinding, and adequacy of analysis. The Table 1 . End points and definitions used for the current meta-analysis. (6) www.americantherapeutics.com analysis was considered adequate if all the patients included were analyzed in the same group to which they were originally allocated regardless of the treatment given to them (intention-to-treat analysis). If the investigators responsible for patient selection were not able to suspect the forthcoming treatment before allocation, then the concealment of allocation was considered adequate.
Data abstraction
We used a standardized data abstraction form for gathering the name of the trial, the authors, trial design, primary and secondary outcomes, funding sources, and treatment regimens.
Statistical analysis
As a result of the lack of patient-level data from each trial, meta-analysis of summary statistics from individual trials was performed. Heterogeneity of the studies was analyzed (Table 3 ) by Cochrane's Q statistics using Comprehensive Meta-Analysis software (Biostat, Englewood, NJ). The studies were homogenous for each outcome; therefore, the Mantel-Hansel fixed-effect model was used to compute common relative risk. A two-sided alpha error of less than 0.05 was considered to be statistically significant (P , 0.05).
RESULTS
The reviewing process is outlined in Figure 1 . From a total of 488 initial citations, 452 were excluded at the title/abstract level and 29 after further careful appraisal, leading to inclusion of six published trials and one abstract in final analysis. [11] [12] [13] [14] [15] [16] [17] Included studies varied in size from 191 to 525 patients, for a total of 2412 patients, 1282 patients randomized to heparin and 1130 to control treatment.
Clinical outcome
The characteristics of individual trials are shown in Table 4 .
11-17 Meta-analytic pooling results are shown in Figures 2-4 . There were no significant differences in patient demographics between both groups.
Ischemic complications
The risk of ischemic complications was similar in both heparin infusion and placebo groups (relative risk, 0.95; confidence interval, 0.46-1.96; P = 0.89; Fig. 2 ).
Vascular complications
Compared with placebo, the risk of major vascular complication was significantly higher in patients getting postprocedural UFH for prolonged hours (relative risk, 2.24; confidence interval, 1.68-3.48; P = 0.001; Fig. 3 ).
DISCUSSION
We found that prolonged heparin infusion increases risk of vascular complications, whereas it may not decrease the risk of ischemic complications. However, the increase in vascular complications was mainly seen in older studies [12] [13] [14] and the most recent study in our analysis by Juergens et al did not find an increase in major vascular/bleeding complications with the routine use of postprocedural UFH after PCI. Although the earlier studies concluded there were increased bleeding complications, these appeared to be only in hematomas, because the only study to fully define such complications 12 concluded there was no increase in major bleeding or vascular injury in the postprocedural UFH group with an incidence of 1% in each group. Juergens et al 11 observed an apparently higher incidence of major vascular complications (5.2% and 4.5% in the UFH and no UFH groups, respectively) when compared with the 0.3% to 6% incidence quoted in other coronary intervention trials. 12, [18] [19] [20] [21] This difference was most likely the result of ascertainment bias through the routine use of vascular ultrasound by Juergens et al. 11 The majority of patients were managed conservatively because approximately half of the major vascular complications identified in their study were not clinically suspected and were only detected by protocol mandated vascular ultrasound. No patient in their study required surgical repair for vascular complication, whereas the need for surgical repair of vascular complications in previous series has ranged from 0.7% to 3.8%. [18] [19] [20] [21] However, there was a trend to a greater fall in postprocedural hemoglobin in the randomized UFH subset suggesting there may have been a difference in more minor bleeding, which was not specifically measured in the Juergens et al study. A similar finding was noted in the study of Rabah et al. 12 Although we found a significant hazard with respect to vascular/bleeding complications by the routine use of postprocedural UFH, there did not appear to be any benefit with respect to a reduction in major ischemic cardiac events. This is consistent result in both the earlier studies from the prestent era as well as the most recent study by Juergens et al 11 in which most of the FIGURE 1. Study selection process. www.americantherapeutics.com American Journal of Therapeutics (2010) 17 (6) patients underwent stents in coronary arteries. The older studies also found no reduction in major adverse cardiac events through the routine use of UFH after the procedure.
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The use of routine postprocedural intravenous UFH has been reported in 39% to 70% of PCIs. 22, 23 UFH exerts its anticoagulant effect by potentiating the effects of antithrombin III on factor Xa and thrombin. 24 It has been used since the advent of PCI to inhibit plateletrich thrombus formation both at the site of balloon injury and on angioplasty equipment. 25, 26 In vivo studies have confirmed a dose-dependent reduction in thrombin activity at the site of balloon injury after heparin administration, 27, 28 and clinical angioplasty studies have demonstrated a reduction in coronary sinus fibrinopeptide A concentrations confirming effects of bolus heparin on thrombin activity. 29 Unfortunately, the effect of heparin in vivo is not completely predictable and is influenced by several factors, including differences in body mass, the clinical scenario-particularly acute coronary syndromes, which can increase heparin resistance-and concomitant use of other drugs, especially nitrates and thrombolytic agents. 30, 31 Its effect is also influenced by concentrations of platelet (6) www.americantherapeutics.com factor 4 and, unlike direct thrombin inhibitors, it is unable to inhibit clot bound thrombin.
32
Much of the data regarding heparin administration during PCI were obtained before the introduction of coronary stenting and potent antiplatelet agents, and there are preliminary data suggesting that heparin itself could play a role in increasing platelet responsiveness. 33 A recent study by Stabile et al 34 was quite provocative in which authors suggested that PCI can be performed with no anticoagulation altogether. This study involved 700 patients on aspirin and thienopyridine therapy who were assigned either to the control arm (70 to 100 UI/kg UFH) or to the no-heparin arm. A clinical assessment was obtained before hospital discharge and at 30 days after PCI. The periprocedural MI rate was significantly higher in the heparin versus the placebo group (3.1% versus 1.7%; P , 0.05). At 30 days, the primary end point was more frequent in the standard anticoagulation than in the no-anticoagulation group (respectively, 2.0% versus 3.7%, absolute risk reduction 1.7% [95% confidence interval, 0.1%-4.5%], P for superiority ,0.17, P for noninferiority ,0.001). Of note, no patients experienced a postprocedural Q-wave acute MI. The authors concluded that in the treatment of uncomplicated lesions and in the presence of dual antiplatelet therapy, elective PCI can be safely performed without systemic anticoagulation and is associated with a reduced incidence of bleeding complications. However, it has to be noted that this study included patients undergoing elective PCI to treat chronic coronary artery disease. The thrombotic milieu of stable and unstable patients is substantially different and justifies different levels of anticoagulation to safely perform coronary interventions in these settings.
Like with any meta-analysis, one of the limitations of our study is the difference in the definitions of the end points in the component trials. Similarly, baseline characteristics between the two groups cannot be compared completely in most meta-analyses because of differences in the study protocols across the component trials. However, because the component trials in our meta-analysis were randomized, the effect of these limitations should be minimized. Also, there is a potential for publication bias, but the trials in our analysis had different results and it should reduce this potential risk. The biggest drawback of the current meta-analysis is lack of recently published data, because most of these studies were done in prestent era and only one study included GPIIb/IIa inhibitors. Also, inconsistency in the timing of sheath removal and vascular closure device used may affect the rate of bleeding complications.
CONCLUSIONS
This meta-analysis confirms that routine infusion of UFH after uncomplicated PCI may result in increased vascular complications without any reduction in incidence of ischemic complications. Larger randomized, controlled trials in the current era of drug-eluting stents, thienopyridines (clopidogrel, prasugrel), and GPIIb/IIIa inhibitor use are required to assess the safety and efficacy of routine infusion and noninfusion of UFH after uncomplicated PCI.
